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Abstract
Objective: To describe obstetrician-gynecologists’ practices and attitudes related to opioid use 
among pregnant and postpartum women.
Study Design: A 2017 cross-sectional survey assessed U.S. obstetrician-gynecologists’ (n=462; 
response rate=34%) practices (management) and attitudes (knowledge, preparedness, confidence, 
barriers, and resources needed) related to opioid use among pregnant and postpartum women. 
Modified Poisson regression determined adjusted prevalence ratios (aPR) for advising medication 
assisted therapy (MAT) for pregnant women with opioid use disorder (OUD) by knowledge, 
confidence, and preparedness.
Results: Of respondents, 33% usually or always advised MAT to pregnant women with OUD. 
Confidence in treating pregnant women who use opioids (aPR: 1.3, 95% CI: 1.0-1.8) and 
knowledge that substance use services were covered under the Affordable Care Act (aPR: 1.4, 
95% CI: 1.1-1.8) were associated with advising MAT.
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Conclusion: Evidence suggests that efforts are needed to enhance physician confidence to 
manage pregnant and postpartum patients who use opioids, which may increase optimal care of 
this patient population.
Introduction
Opioid use and opioid use disorder during pregnancy are not only associated with adverse 
maternal outcomes such as co-substance use, and obstetrical morbidities and mortality, but 
also with infant outcomes such as neonatal abstinence syndrome (NAS), preterm birth, and 
stillbirth (1, 2). Opioid use disorder, as defined by the current Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), is “ … a problematic pattern of opioid use leading to 
clinically significant impairment or distress….” characterized by meeting at least 2 of 11 
defined criteria (e.g., craving or strong desire or urge to use) within a 12 month period (3). 
The prevalence of maternal opioid use disorder has increased significantly from 1.5 to 6.5 
per 1,000 hospital deliveries from 1999 to 2014 (4). Rates of NAS, which is primarily a 
result of in-utero opioid exposure, have increased in parallel from 1.2 to 8.0 per 1,000 
deliveries from 2000 to 2014 (1, 5). Appropriate management of women who use opioids 
and women with opioid use disorder is important for pregnancy and postpartum health and 
birth outcomes for the maternal and infant dyad.
In 2017, the American College of Obstetricians and Gynecologists (ACOG) and the 
American Society of Addiction Medicine (ASAM) published recommendations for 
screening and management of pregnant and postpartum women with opioid use and opioid 
use disorder (6). During pregnancy, screening is recommended for opioid use and opioid use 
disorder, other substance use, and co-occurring mental health conditions (6). For chronic 
pain, ACOG/ASAM advise physicians to avoid or minimize the use of opioids for pain 
management (6); thus, any use of opioids during pregnancy, even use as prescribed, may 
require specialized care. ACOG and ASAM guidelines acknowledge that medication-
assisted treatment (MAT), also referred to as opioid agonist pharmacotherapy, “…with either 
methadone or buprenorphine has been used for treatment of opioid use disorder in pregnant 
women.”(6) As more safety data become available, use of the combination of buprenorphine 
and naloxone during pregnancy may increase (6). The preferred management of opioid use 
disorder during and after pregnancy is MAT (6) as it is associated with an increased 
likelihood of adherence to prenatal care and addiction treatment programs (6), retention of 
maternal guardianship (7), and a reduction in the risk of obstetric complications (8, 9) and 
perinatal adverse outcomes (7). Abrupt cessation or tapering of opioids can result in severe 
withdrawal symptoms and is associated with high rates of relapse (6, 8). Little is known 
about the current management of pregnant women with opioid use disorder, including how 
often MAT is advised and how often screening for comorbidities occurs. In addition, it is 
unclear how management of opioid use disorder during pregnancy is affected by physicians’ 
perceptions of preparedness and how confident they are to treat pregnant women who use 
opioids. The Affordable Care Act of 2010 included provisions that require Medicaid-insured 
individuals receive coverage for comprehensive substance use services, including both 
counseling and pharmacotherapy; this would include women receiving Medicaid coverage 
during their pregnancy. It is unknown whether physician-reported knowledge of this 
coverage provision is associated with management of opioid use disorder during pregnancy.
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ACOG and ASAM recommendations specific to the postpartum period for women with 
opioid use disorder include promoting continuation of MAT, counseling on contraception, 
and encouraging women on MAT without other contraindications to breastfeed (6). For all 
women, the postpartum period may be an optimal time to counsel and provide contraception 
to those who desire it to avoid negative outcomes related to short birth intervals (10, 11). 
Absent contraindications, breastfeeding is encouraged for all maternal and infant dyads as it 
offers immunity and supports maternal and infant attachment (12). For women on MAT, 
breastfeeding is associated with decreased severity of their infants’ withdrawal signs (i.e., 
NAS) and is one of many nonpharmacologic treatment strategies to reduce an infant’s need 
for pharmacotherapy (13-15). Scant information exists on whether physicians are counseling 
postpartum contraception or breastfeeding for women with opioid use disorder. In addition, 
barriers experienced by physicians when treating pregnant and postpartum women for opioid 
use disorder and physician’s opinions on what resources are needed to improve treatment 
have not been documented on a national scale.
In a preceding analysis, we investigated uptake of ACOG’s universal substance use 
screening recommendations and found that 79% of respondents reported frequently 
screening for substance use among their pregnant patients (16). We also found that 55% and 
61% of obstetrician-gynecologists perceived that screening for medical and non-medical use 
of prescription opioids, respectively, is a high priority for their practices. In the present 
analysis, we describe the management of pregnant and postpartum women with opioid use 
disorder, as defined in our survey and as reported by obstetrician-gynecologists, and whether 
their confidence in treating women who use opioids, their perceived preparedness to 
prescribe MAT for pregnant women with opioid use disorder, and their knowledge of service 
coverage are associated with advising MAT. In addition, we describe physicians’ perceived 
barriers to screening and treatment, and perceived resources needed to improve treatment. 
Findings from this study can guide efforts for education, training, and support for physicians 
to effectively manage opioid use among pregnant and postpartum women to improve their 
treatment and health outcomes.
Materials and Methods
Survey Design
Investigators from ACOG and the Centers for Disease Control and Prevention (CDC) 
collaboratively developed a cross-sectional survey to assess obstetrician-gynecologists’ 
reported experiences, opinions, and practices regarding women’s substance use during 
pregnancy and postpartum. Specifically, the survey included questions about frequency and 
method of substance use screening (e.g., alcohol, tobacco, marijuana, illicit substances), 
which are reported elsewhere (16), and questions on practices, knowledge, perceptions of 
preparedness and confidence for managing opioid use among pregnant and postpartum 
women, and potential resources needed for and barriers to effective treatment of opioid use 
disorder, which are reported on in this manuscript. ACOG received local IRB approval; 
survey completion was considered consent to participate. Additional methodological details 
regarding survey design and participants can be found elsewhere (16).
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Measures
Survey questions relevant to the current analysis included: (a) management of pregnant and 
postpartum women with opioid use disorder, where respondents were asked to consider 
“How do you manage pregnant patients who have opioid use disorders (illicit use or 
nonmedical use of prescription opioids)?”; b) confidence in treating pregnant women who 
use opioids; (c) perceptions of preparedness to screen for opioid use disorder, conduct brief 
interventions with those who use opioids, educate on effects of opioids and on breastfeeding, 
use resources, and prescribe MAT for pregnant and postpartum women with opioid use 
disorder (d) a medical practice’s priority of screening for medical and non-medical use of 
prescription opioids; (e) knowledge of the Affordable Care Act provision for plans to cover 
comprehensive substance use services for pregnant women on Medicaid; and (f) perceived 
barriers to screening and treating pregnant and postpartum women with opioid use disorder 
and resources needed to improve treatment. Questions and categorization of responses can 
be found in Table 1.
Statistical Analyses
Frequencies were calculated of respondents’ self-reported management, confidence and 
perceptions of preparedness, practice’s screening priority for medical and non-medical use 
of prescription opioids, and perceived barriers and resources needed to improve treatment 
for opioid use disorder. Pearson chi-squared tests were used to assess associations between 
perceptions of preparedness and confidence in treating pregnant women who use opioids. 
Our outcome of interest, advising of MAT, was defined as usually or always advising 
methadone or buprenorphine, due to evolving evidence related to use of the combination of 
buprenorphine and naloxone during pregnancy. Poisson regression with a robust error 
variance, or Modified Poisson Regression, was used to determine the association between 
advising MAT for pregnant women with opioid use disorder and confidence in treating 
pregnant women who use opioids, perceived preparedness for prescribing MAT, practice 
priority for screening for medical and non-medical use of prescription opioids, and 
knowledge of the coverage of comprehensive substance use services, controlling for 
physician characteristics (sex, race, board certification, and years of practice), patient 
population (percentage of patient’s race identified as white, and Medicaid enrollees), and 
practice characteristics (practice type, average number of new pregnant patients per month, 
region, and location). A 2-tailed probability of less than 0.05 was considered statistically 
significant. Data were analyzed with SAS software (version 9.4; SAS Institute Inc., Cary, 
NC).
Results
The overall response rate was 34% (N = 462). Respondents had a mean of 20 years in 
practice, 63% were female, and 12% were board certified in maternal-fetal medicine (data 
reported elsewhere) (16). More than 72% of respondents indicated that over a quarter of 
their patients were insured by Medicaid (16).
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Management of Pregnant and Postpartum Women with Opioid Use Disorder
For pregnant women with opioid use disorder, most respondents indicated that they usually 
or always advise opioid cessation (55%), sometimes advise methadone or buprenorphine 
maintenance (36%–41%), and never or rarely advise inpatient, monitored withdrawal (58%) 
or buprenorphine and naloxone together (48%) (Table 2). Most respondents indicated they 
usually or always screen for alcohol/tobacco, depression, anxiety, and intimate partner 
violence (>75%) and never or rarely conduct brief interventions or motivational interviews 
(52%). Almost all respondents reported usually or always informing these women about the 
fetal effects of opioids (93%).
For postpartum women with opioid use disorder, most respondents indicated that they 
usually or always advise opioid cessation (68%), sometimes advise methadone or 
buprenorphine (40%–45%), and rarely or never advise inpatient, monitored withdrawal 
(48%) (Table 2). Most respondents reported that they usually or always recommend 
breastfeeding for those on MAT (53%), counsel on effective contraceptive methods (96%), 
refer the women to a treatment program or facility (59%) or addiction specialist (61%), and 
sometimes refer the women to psychiatry (42%).
Perceptions of Preparedness, Confidence in Treating, and Knowledge of Comprehensive 
Treatment Provision Insurance Coverage
A high proportion of respondents felt prepared to screen pregnant (82%) and postpartum 
(75%) women for opioid use disorder and educate pregnant (89%) and breastfeeding (72%) 
patients about the effects of opioids on their fetus or baby (data not shown). Most 
respondents felt prepared to conduct brief intervention with pregnant women who use 
opioids (66%) and use resources to refer patients who need an opioid cessation program 
(65%). Fewer respondents felt prepared to prescribe MAT to pregnant (22%) and 
nonpregnant (17%) women (data not shown).
Overall, 37% of respondents felt confident in treating pregnant women who use opioids 
(data not shown). Respondents who reported feeling confident treating pregnant women who 
use opioids were significantly more likely than their counterparts to feel prepared to conduct 
brief interventions with those who use opioids (85% vs. 54%, P < 0.001), use resources to 
refer women who need an opioid cessation program (88% vs. 50%, P < 0.001), and prescribe 
MAT for pregnant women with opioid use disorder (40% vs. 11%, P < 0.001) (data not 
shown).
A quarter of respondents knew of the Affordable Care Act provision for coverage of 
comprehensive substance use services for Medicaid-insured individuals, which would 
include pregnant women. Most respondents did not know (71%) or incorrectly stated that the 
provision did not exist (4%) (data not shown).
Advising MAT
Overall, nearly 33% reported usually or always advising some form of MAT to their 
pregnant patients with opioid use disorder (Table 2). After controlling for physician, patient 
population, and practice characteristics, respondents who felt confident in treating pregnant 
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women who use opioids were 1.3 times as likely to advise MAT for their pregnant patients 
with opioid use disorder as respondents who did not feel confident treating these women 
(95% CI: 1.0, 1.8, P = 0.04) (Table 3). Respondents who were knowledgeable about the 
Affordable Care Act provision requiring pregnant women on Medicaid to receive coverage 
for comprehensive substance use services were 1.4 times as likely to advise MAT for their 
pregnant patients as those who were not knowledgeable about this provision (95% CI: 1.1, 
1.8) (Table 3). No significant difference was seen in advising MAT by perceived 
preparedness to prescribe MAT for patients (aPR: 1.1, 95% CI: 0.8, 1.5) or perceived 
practice priority for screening for medical and non-medical use of prescription opioids (aPR: 
0.8, 95% CI: 0.6, 1.1) (Table 3).
Barriers to Screening and Treating and Resources Needed to Improve
The most frequently reported barriers to screening and treating pregnant and postpartum 
women for opioid use disorder were patient denial or resistance (62%), a lack of facilities or 
resources for treatment of opioid use disorder once identified (58%), patient’s inability to 
pay (51%), and time limitations during patient visits (51%) (Figure 1). Less than 20% of 
respondents reported that state reporting laws and concerns about patient confidentiality 
issues were barriers to screening and treatment. The most frequently chosen responses for 
resources needed to improve treatment of opioid use disorder in clinical practice were: (a) 
referral resources and treatment facilities for pregnant and postpartum women with opioid 
use disorder (85%); (b) patient information about adverse reproductive outcomes associated 
with opioids (65%); and (c) specific standardized screening questionnaires for substance use 
during pregnancy (64%) (Figure 2).
Comment
Among a national sample of obstetrician-gynecologists, approximately one third and one 
quarter of respondents reported advising MAT for their pregnant and postpartum patients, 
respectively, with opioid use disorder. Half of physicians frequently advised cessation 
among pregnant women with opioid use disorder. After adjustment for other factors, 
confidence in treating pregnant women who use opioids was associated with higher 
prevalence of advising MAT. Findings suggest a need to educate and increase the confidence 
of physicians to provide MAT both during and after pregnancy to ensure optimal outcomes 
for both mother and baby, and to reduce relapse and overdoses. Unmet treatment needs 
remain high among women, ranging from 81% to 95% across states (17). As obstetricians 
and gynecologists are often the first contact into care for pregnant women, increasing 
capacity at prenatal clinics to provide MAT may be an important strategy to address opioid 
use disorder among this population. Training resources are available online for the 
appropriate management and treatment of pregnant and postpartum women who have opioid 
use disorder (https://www.cdc.gov/drugoverdose/training/pregnancy/) and on buprenorphine 
waivers (https://www.samhsa.gov/medication-assisted-treatment/training-resources/
buprenorphine-physician-training). However, simply increasing the number of 
buprenorphine waivered providers may not necessarily increase the number of women 
treated (18). Additional ways to increase physician confidence and MAT integration into 
obstetric practices may include the use of provider warm lines to deliver real time support to 
Ko et al. Page 6
J Perinatol. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the clinic and assistance linking obstetric practices with addiction treatment. The 
Massachusetts Child Psychiatry Access Program for Moms, is an innovative example of 
building capacity within perinatal primary care providers to address perinatal mental health 
and substance use through the provision of near-time telephonic clinical consultations from 
perinatal psychiatrist colleagues, as well as provision of trainings, tool kits, and referrals to 
community resources (19). Obstetrician-gynecologists frequently screen for substance use 
(16). Taking patient histories and using verbal screening tools provide the opportunity for 
the prenatal care clinician to offer brief intervention or motivational interviewing (6, 20). 
Brief behavioral counseling interventions have been shown to be effective in reducing 
drinking (21, 22), smoking (23, 24), and illicit drug use (25) during pregnancy and to 
improve pregnancy outcomes (26). However, more than half of respondents in our study 
reported a low frequency of conducting brief intervention or performing motivational 
interviewing or cognitive behavioral therapy, potentially due to the time-consuming nature 
of these activities or referral to treatment centers or addiction specialists. Almost all 
respondents frequently informed their pregnant patients about the fetal effects of opioid use 
during pregnancy; however, two thirds of respondents identified needing patient information 
about adverse reproductive outcomes associated with opioids. In addition, respondents cited 
patient denial or resistance as the most commonly reported barrier to screening and 
treatment. Thus, intervention strategies that address how physicinas can create open patient 
provider dialogues with their patients may be important to consider.
Nearly all respondents reported, for the postpartum period, frequently counseling their 
patients on effective postpartum contraceptive methods (96%), but only half of respondents 
reported frequent recommendation of breastfeeding to their patients on MAT (53%). The 
low rate of breastfeeding recommendation may be due to the increased likelihood that 
women with opioid use disorder have contraindications, such as HIV (6). ACOG encourages 
physicians to discuss with their patients, preferably during the prenatal period, all 
contraceptive options and to encourage breastfeeding if a woman is stable on MAT, not 
using illicit substances, and HIV negative (6). Continuing education and training may 
increase use of brief interventions and encouragement of breastfeeding, if appropriate.
Six out of ten physicians reported always referring postpartum patients with OUD to 
treatment services. Additionally, lack of treatment facilities and referral resources was the 
second most common perceived barrier reported. Most physicians cited that they needed 
referral resources and treatment facilities to improve treatment of women with opioid use 
disorder. In combination, these findings may reflect a perceived lack of available treatment 
centers or a missing linkage between prenatal care and addiction treatment. ACOG 
guidelines state that obstetrician-gynecologists should be knowledgeable about local 
resources for substance use treatment and that proper case communication with physicians at 
substance treatment facilities can optimize patient care (6). It is uncommon for US medical 
centers and obstetrician-gynecologist practices to have the resources to support in-house 
perinatal addiction treatment programs (27), but there is growing recognition for the need of 
improved coordinated care and wrap around services. Warm lines and state perinatal access 
programs may assist in referrals and connection to treatment facilities. The Opioid Use 
Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning 
Community is one example of public health efforts to address discontinuity of care. States 
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teams participating in this collaborative are composed of state Medicaid medical director, 
behavioral, mental health, or alcohol and drug abuse director, Title V director, and a provider 
or facility champion (28). These state teams are working to implement strategies such as: 
development of a MAT provider network map for pregnant and postpartum women with 
OUD, implementation of a care bundle to address OUD, and waiving prior authorization 
prescribing requirements for MAT (28) Furthermore, state or regional perinatal quality 
collaboratives (multidisciplinary state or regional teams composed of obstetrician-
gynecologists, neonatologists, pediatricians, hospital leaders, patient representatives, and 
community organizations) may be useful in standardizing protocols that promote continuous 
care for pregnant and postpartum women and their infants across hospitals and outpatient 
clinics. Additionally, state chapters of professional organizations may wish to provide joint 
trainings so that members have opportunities to establish ongoing relationships.
About half of our respondents identified reimbursement by insurance for screening and 
treatment, and access to phone consultation to ask questions, as useful resources. Increasing 
awareness of the Affordable Care Act provision for comprehensive substance use coverage 
among Medicaid-insured individuals, which includes women receiving coverage for their 
pregnancy, may be beneficial as only a quarter of respondents were aware of this provision. 
Several states are exploring strategies to address the increased risk of overdose in the 
postpartum period and the need for continuity of care. These strategies include: providing 
and reimbursing integrated wraparound services for pregnant and postpartum women and 
their infants, and working with insurers, including Medicaid to ensure full insurance 
coverage up to 1 year postpartum (28). However, a study of MAT providers, opioid 
treatment programs, and outpatient buprenorphine providers in four Appalachian states 
found that opioid treatment programs were less likely to treat pregnant women and accept 
either Medicaid or private insurance (29). Thus, addressing reimbursement and payment 
structure through novel reimbursement mechanisms such as the unbundling of prenatal care 
from addiction treatment (if provided at the same time and space by the same provider), or 
value based payment for the prescription of MAT may be important to consider.
This study provides information on participating obstetrician-gynecologists’ practices 
related to opioid use during pregnancy and postpartum. There are a few limitations. First the 
34% response rate may result in nonresponse bias, and our results may not be generalizable 
to all ACOG members. However, nonresponse bias may be less problematic among 
physician populations. Second, self-reported behaviors and management practices may be 
inflated because of social desirability bias (30). Third, wording of some survey questions 
might not have been sufficiently precise to capture compliance with ACOG/ASAM 
guidelines. For example, opioid use disorder was defined for respondents as including illicit 
opioid use or non-medical use of prescription opioids and thus differed from current 
diagnostic criteria (3). Respondents’ interpretations of the survey’s language about opioid 
use disorder might have affected response selections. Physicians choosing responses to 
describe their practices related to patients with illicit opioid use or non-medical use of 
prescription opioids might have underreported their true practice of usually or always 
advising MAT for opioid use disorder as defined in the DSM-5. Similarly, the survey did not 
define “confidence in providing treatment”, but rather left the interpretation of this concept 
to the respondent. Fourth, our estimates may underestimate usually or always advising MAT 
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because we defined MAT conservatively and did not include combination buprenorphine and 
naloxone. Further, physicians may refer their patients with opioid use disorder to a treatment 
program or addiction specialist and might not reflect the care actually received by women. 
Additionally, this survey did not ask physicians specifically about peripartum pain 
management or discharge opioid prescribing for women with OUD. The postpartum period 
is a time of increased vulnerabilities for OUD recurrence, overdose and overdose death, risks 
that are mitigated by medication continuation (31). Finally, these data were collected in 2017 
and may not reflect recent efforts to improve management of opioid use disorder among 
pregnant and postpartum women.
In summary, most of the responding obstetrician-gynecologists reported that some of their 
management of opioid use disorder among pregnant and postpartum women aligned with 
ACOG/ASAM guidelines: screening for other substances and mental health conditions, 
discussing the fetal effects of opioids, and counseling on postpartum contraception. 
However, findings appear to indicate there are key improvement opportunities for 
obstetrician-gynecologists regarding advising MAT, using brief interventions, and advising 
breastfeeding, where appropriate. Evidence from this study suggests that efforts are needed 
to enhance physician confidence to manage pregnant and postpartum patients who use 
opioids, which may increase optimal care of this patient population.
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Figure 1. Major barriers to screening and treating pregnant and postpartum patients for opioid 
use disorder1 (n = 340); Survey of American College of Obstetricians and Gynecologists 
Members, 2017
1
 Participants were asked: To what extent are the following potential barriers to screening 
and treating pregnant and postpartum patients for opioid use disorder?
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Figure 2. Resources needed to improve treatment for pregnant and postpartum patients with 
opioid use disorder1 (n = 337); Survey of American College of Obstetricians and Gynecologists 
Members, 2017
1
 Participants were asked: What resources do you need to improve treatment of opioid use 
disorder in your clinical practice? Check all that apply.
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Table 1.
American College of Obstetricians and Gynecologists survey questions, 2017
Theme Question Answer options Categorization
I. Management 
of patients
How do you manage pregnant patients who have opioid use disorders (illicit 
use or nonmedical use of prescription opioids)?
1 Advise opioid cessation.
2 Advise inpatient, monitored withdrawal.
3 Advise methadone maintenance.
4 Advise buprenorphine maintenance.
5 Advise buprenorphine/naloxone maintenance.
6 Conduct brief intervention/motivational interviewing/
cognitive behavioral therapy.
7 Screen for alcohol or tobacco use.
8 Screen for depression.
9 Screen for anxiety or use of benzodiazepines.
10 Screen for intimate partner violence.
11 Inform about fetal effects (e.g., neonatal abstinence 
syndrome).
A. Never
B. Rarely Never/Rarely
How do you manage postpartum patients who have opioid use disorders 
(illicit use or nonmedical use of prescription opioids)?
1 Advise opioid cessation.
2 Advise inpatient, monitored withdrawal.
3 Advise methadone maintenance.
4 Advise buprenorphine maintenance.
5 Advise buprenorphine/naloxone maintenance.
6 Recommend breastfeeding if on opioid-assisted therapy.
7 Counsel on effective contraceptive methods (e.g., long-acting 
reversible contraceptives, oral contraceptives).
8 Refer to a treatment program or facility.
9 Refer to an addiction specialist.
10 Refer to psychiatry.
C. Sometimes Sometimes
D. Usually
E. Always Usually/Always
II. Confidence 
in treating 
Patients Using 
Opioids
 Do you feel confident that you can appropriately treat your pregnant 
patients who are using the following substances?
1. Opioids
A. Not confident
B. Somewhat 
confident
Not confident
C. Confident
D. Very confident Confident
III. Perceptions 
of 
preparedness
In general, how prepared do you feel to do the following in your clinical 
practice:
1 Screen pregnant patients for opioid use disorder?
2 Conduct brief interventions with pregnant patients who use 
opioids?
3 Educate pregnant patients about the effects of opioids on their 
fetus or baby.
4 Use resources to refer patients who need an opioids cessation 
program.
5 Prescribe opioid-assisted therapy for pregnant patients.
A. Very unprepared
B. Unprepared Unprepared
C. Prepared
D. Very prepared Prepared
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Theme Question Answer options Categorization
6 Screen postpartum patients for opioid use disorder.
7 Educate breastfeeding patients about the effects of opioids on 
their infant.
8 Prescribe opioid-assisted therapy for nonpregnant patients.
IV. Priority of 
screening
To what extent is any routine screening of the following among pregnant 
patients in your practice a priority?
1 Prescription opioid use.
2 Nonmedical use of prescription opioids (i.e., using opioids 
for reasons other than prescribed).
A. Not a priority
B. Moderate 
priority
Not high priority
C. High priority High priority
V. Knowledge
1 Does the Affordable Care Act include a provision that 
requires pregnant patients on Medicaid receive coverage for 
comprehensive substance use services, including both 
counseling and pharmacotherapy?
A. I do not know.
B. No
Not knowledgeable 
about provision
C. Yes Knowledgeable about provision
VI. Barriers 
and resources
To what extent are the following potential barriers to screening and treating 
pregnant and postpartum patients for opioid use disorder?
1 Time limitations during patient visits.
2 Concern about patient confidentiality issues.
3 Patient sensitivity to this topic (e.g., fear of offending 
patients).).
4 Patient denial or resistance.
5 Doubt about the efficacy of brief intervention.
6 Limited training or experience in screening for opioids.
7 Limited training or experience in treating opioid use disorder.
8 Lack of facilities or resources for treatment of opioid use 
disorder, once identified.
9 Lack of or inadequate financial reimbursement for opioid 
screening, assessment, and counseling.
10 Patient inability to pay for treatment.
11 State reporting laws and repercussions.
12 Not sure what screener to use.
13 Other (please specify).
A. Not a barrier
B. Minor barrier Not a major barrier
C. Major barrier Major barrier
What resources do you need to improve treatment of opioid use disorder in your clinical practice? Check all that apply.
1 Patient information regarding adverse reproductive outcomes associated with opioids.
2 Patient information regarding infectious disease associated with use by injection.
3 Referral resources and treatment facilities for pregnant and postpartum patients with opioid use disorder.
4 Access to phone consultation line to ask questions regarding opioid use disorders in pregnant patients.
5 Information regarding relapse prevention for patients who seek treatment for addiction in pregnancy.
6 Specific standardized screening questionnaire for substance use during pregnancy.
7 Training and advice on brief interventions or motivational interviewing.
8 Reimbursement by insurance for screening and assessment.
9 Other (please specify).
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Table 2.
Management of pregnant1 and postpartum2 patients with opioid use disorder; Survey of American College of 
Obstetricians and Gynecologists Members, 2017
Frequency of management
Always/Usually Sometimes Rarely/Never
Pregnant patients1 N N (%) N (%) N (%)
Advise opioid cessation 402 222 (55.2) 85 (21.1) 95 (23.6)
Advise inpatient, monitored withdrawal 387 60 (15.5) 104 (26.9) 223 (57.6)
Advise methadone maintenance 400 131 (32.8) 165 (41.3) 104 (26.0)
Advise buprenorphine maintenance 396 128 (32.3) 141 (35.6) 127 (32.1)
Advise buprenorphine and naloxone maintenance 392 81 (20.7) 125 (31.9) 186 (47.5)
Conduct brief intervention/motivational interviewing/cognitive behavioral therapy 395 101 (25.6) 87 (22.0) 207 (52.4)
Screen for alcohol or tobacco use 338 314 (92.9) 17 (5.0) 7 (2.1)
Screen for depression 406 360 (88.7) 35 (8.6) 11 (2.7)
Screen for anxiety or use of benzodiazepines 404 329 (81.4) 56 (13.9) 19 (4.7)
Screen for intimate partner violence 406 315 (77.6) 63 (15.5) 28 (6.9)
Inform about fetal effects (e.g., neonatal abstinence syndrome) 407 377 (92.6) 20 (4.9) 10 (2.5)
Postpartum patients2 N N (%) N (%) N (%)
Advise opioid cessation 395 267 (67.6) 65 (16.5) 63 (16.0)
Advise inpatient, monitored withdrawal 382 65 (17.0) 133 (34.8) 184 (48.2)
Advise methadone maintenance 388 98 (25.3) 175 (45.1) 115 (29.6)
Advise buprenorphine maintenance 382 90 (23.6) 154 (40.3) 138 (36.1)
Advise buprenorphine and naloxone maintenance 381 77 (20.2) 154 (40.4) 150 (39.4)
Recommend breastfeeding if on opioid-assisted therapy 383 201 (52.5) 90 (23.5) 92 (24.0)
Counsel on effective contraceptive methods 398 383 (96.2) 13 (3.3) 2 (0.5)
Refer to a treatment program or facility 387 230 (59.4) 121 (31.3) 36 (9.3)
Refer to addiction specialist 393 239 (60.8) 101 (25.7) 53 (13.5)
Refer to psychiatry 389 149 (38.3) 164 (42.2) 76 (19.5)
1
Participants were asked: How do you manage pregnant patients who have opioid use disorders (illicit use or nonmedical use of prescription 
opioids)?
2
Participants were asked: How do you manage postpartum patients who have opioid use disorders (illicit use or nonmedical use of prescription 
opioids)?
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Table 3.
Characteristics associated with physicians usually or always advising MAT (methadone or buprenorphine) to 
pregnant patients with opioid use disorder1 (n = 265); Survey of American College of Obstetricians and 
Gynecologists Members, 2017
Physician characteristics aPR2 (95% CI)
Confident in treating pregnant patients using opioids3 1.3 (1.0, 1.8)
Feels prepared to prescribe MAT for pregnant patients4 1.1 (0.8, 1.5)
High practice priority to screen for medical use and non-medical use of prescription opioids5 0.8 (0.6, 1.1)
Knowledge of comprehensive substance use ACA provision6
 Not knowledgeable about provision Ref.
 Knowledgeable about provision 1.4 (1.1, 1.8)
Physician female sex 1.0 (0.7, 1.3)
Physician white race or ethnicity 1.1 (0.8, 1.7)
Maternal-fetal medicine board-certified 1.0 (0.7, 1.4)
Years since residency completed
 ≥ 20 years Ref.
 < 20 years 1.0 (0.8, 1.4)
Patient population characteristics aPR2 (95% CI)
Patients white race or ethnicity
 0%–%–25% Ref.
 26%–50% 1.2 (0.8, 1.9)
 51%–100% 1.1 (0.7, 1.7)
Patients on Medicaid
 0%–25% Ref.
 26%–50% 1.8 (1.2, 2.7)
 51%–100% 1.5 (1.0, 2.3)
Practice characteristics aPR2 (95% CI)
Practice type
 Solo practice 1.2 (0.8, 1.8)
 Nonsolo practice Ref.
Number of pregnant pregnant patients per month
 <15 Ref.
 ≥15 1.2 (0.9, 1.6)
US region
 Midwest Ref.
 Northeast 1.3 (0.9, 1.8)
 South 1.0 (0.7, 1.5)
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Physician characteristics aPR2 (95% CI)
 West 1.1 (0.7, 1.6)
Location
 Urban Ref.
 Suburban 0.9 (0.6, 1.3)
 Mid-sized town/rural/military 1.2 (0.9, 1.8)
ACA: Affordable Care Act; aPR: adjusted prevalence ratio; MAT: medication-assisted treatment
1
Participants were asked: How do you manage pregnant patients who have opioid use disorders (illicit use or nonmedical use of prescription 
opioids)?
2
aPR estimated by using Poisson regression with a robust error variance, adjusted for physician, patient population, and practice characteristics.
3
Participants were asked: Do you feel confident that you can appropriately treat your pregnant patients who are using the following substances?
4
Participants were asked: In general, how prepared do you feel to do the following in your clinical practice: Prescribe opioid-assisted therapy for 
pregnant patients
5
Participants were asked: To what extent is any routine screening of the following among pregnant patients in your practice a priority
6
Participants were asked: Does the Affordable Care Act include a provision that requires pregnant patients on Medicaid receive coverage for 
comprehensive substance use services, including both counseling and pharmacotherapy?
Bold aPR indicates significant at P < 0.05.
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